Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00546780 · ClinicalTrials.gov registry record · Phase 3
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
A Phase 3 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
- 19
- Study locations
NCT00546780 is a Phase 3 study of Multiple Myeloma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 31 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The trial reports 19 study locations across 16 states.
The verdict
NCT00546780, a Phase 3 study of Multiple Myeloma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is a phase 3, open label trial for patients with multiple myeloma in first relapse. Trial will compare tanespimycin (KOS-953), in combination with a fixed dose of bortezomib versus bortezomib alone.
Conditions Studied
Interventions
- DRUG Bortezomib
- DRUG Tanespimycin
Study Locations (19)
California
- Comprehensive Blood And Cancer Center - Bakersfield
- Moores Ucsd Cancer Center - La Jolla
- University Of California Medical Center - San Francisco
Tennessee
- Tennessee Cancer Specialists - Knoxville
- Sarah Cannon Research Institute - Nashville
Colorado
- Rocky Mountain Cancer Centers - Denver
Iowa
- University Of Iowa Hospitals And Clinics - Iowa City
Kansas
- University Of Kansas Medical Center - Westwood
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Henry Ford Health System Irb - Detroit
Missouri
- Capitol Comprehensive Cancer Care Center - Jefferson City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00546780
The ClinicalTrials.gov registry entry for NCT00546780 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Bortezomib is the first listed.
NCT00546780 reports 19 study locations spanning 16 distinct geographic areas - top geographies include California, Tennessee, Colorado.
Frequently Asked Questions
What is clinical trial NCT00546780 about?
NCT00546780 is a clinical study titled "A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse". This is a phase 3, open label trial for patients with multiple myeloma in first relapse. Trial will compare tanespimycin (KOS-953), in combination with a fixed dose of bortezomib versus bortezomib alone.
What is the current status of trial NCT00546780?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 2008-02. Estimated completion is 2010-03.
What conditions does trial NCT00546780 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00546780?
The interventions under investigation include: Bortezomib (DRUG), Tanespimycin (DRUG).
Who is sponsoring clinical trial NCT00546780?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00546780 being conducted?
This trial has 19 study locations across California, Colorado, Iowa, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.